{
    "title": "114_hr639",
    "content": "The Act is titled the \"Improving Regulatory Transparency for New Medical Therapies Act.\" It amends the Federal Food, Drug, and Cosmetic Act to include scheduling of substances in new FDA-approved drugs. The effective date of drug approval is specified, especially in cases where recommended controls under the CSA are involved. The Act, titled the \"Improving Regulatory Transparency for New Medical Therapies Act,\" amends the Federal Food, Drug, and Cosmetic Act to include scheduling of substances in new FDA-approved drugs. Approval of a drug under subsection (b) is delayed if the Secretary intends to issue a scientific evaluation and recommend controls under the Controlled Substances Act. The date of approval is determined by the later of the approval under subsection (c) or the issuance of the interim final rule controlling the drug. The Act, titled the \"Improving Regulatory Transparency for New Medical Therapies Act,\" amends the Federal Food, Drug, and Cosmetic Act to include scheduling of substances in new FDA-approved drugs. The date of approval for biological products is determined by the later of the approval under subsection (c) or the issuance of the interim final rule controlling the drug. The Act amends the Federal Food, Drug, and Cosmetic Act to include scheduling of substances in new FDA-approved drugs. Approval of a biological product is delayed until the interim final rule controlling the product is issued under the Controlled Substances Act. The date of approval for a biological product is determined by the later of the approval of the application or the issuance of the interim final rule controlling the product under the Controlled Substances Act. The date of approval for a drug under the Controlled Substances Act is tied to the issuance of the interim final rule controlling the drug. The Controlled Substances Act links the date of approval for a drug to the issuance of the interim final rule controlling the drug. Additionally, conditional approval for a drug application is addressed in Section 571(d) of the Federal Food, Drug, and Cosmetic Act. The Controlled Substances Act ties drug approval to the issuance of the interim final rule. Conditional approval of a drug application is discussed in Section 571(d) of the Federal Food, Drug, and Cosmetic Act. The Controlled Substances Act links drug approval to the issuance of the interim final rule. Conditional approval of a drug application is defined in Section 571(d) of the Federal Food, Drug, and Cosmetic Act. The term 'date of approval' for an application means the later of the conditional approval date or the date of the interim final rule controlling the drug. Additionally, Section 572 of the Act addresses the indexing of legally marketed unapproved new animal drugs. The Controlled Substances Act requires that a drug be linked to the issuance of an interim final rule before approval. This rule applies to requests to add a drug to the index under certain conditions. The approval of such requests will not take effect until the interim final rule controlling the drug is issued. According to the Controlled Substances Act, a drug must be associated with the issuance of an interim final rule before approval. This rule applies to requests to add a drug to the index under specific conditions, and approval will only occur once the interim final rule controlling the drug is issued. The Controlled Substances Act requires an interim final rule to be issued before a drug can be approved. If the Secretary of Health and Human Services recommends controlling a drug in schedule II, III, IV, or V, the Attorney General must issue an interim final rule within 90 days. The Attorney General must issue an interim final rule controlling a drug within 90 days of receiving the scientific evaluation and scheduling recommendation from the Secretary of Health and Human Services. The Attorney General must issue an interim final rule controlling a drug within 90 days of receiving notification from the Secretary of Health and Human Services approving an application under certain acts or indexing a drug. The rule becomes immediately effective without needing to demonstrate good cause. The interim final rule issued by the Attorney General for controlling a drug shall become effective immediately without the need to demonstrate good cause. Interested persons can comment and request a hearing before a final rule is issued. The interim final rule issued by the Attorney General for controlling a drug becomes effective immediately upon notice to the sponsor of the drug product. The rule allows for comments and hearings before final implementation. The interim final rule issued by the Attorney General for controlling a drug becomes effective immediately upon notice to the sponsor of the drug product. The rule allows for comments and hearings before final implementation. For products recommended for controls under the Controlled Substances Act, upon the covered date, the drug product is considered approved under relevant provisions of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act, with permission for commercial marketing or use. The term 'covered date' refers to the later date of application approval under specified sections of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. Enhancing new drug development includes conditions for approval under specific sections of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act, as well as the date of issuance of the interim final rule controlling the drug under the Controlled Substances Act. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT. Amends Section 303 of the Controlled Substances Act to expedite registration for manufacturing controlled substances for clinical trials. The Attorney General must issue a notice of application within 90 days after accepting an application for manufacturing a controlled substance for clinical trials. Registration or an order to show cause will be issued within 90 days after the comment period ends, unless a hearing is granted. Section 304(c) requires a hearing granted by the Attorney General under section 1008(i) of the Controlled Substances Import and Export Act. Section 1003 is amended to allow re-exportation among members of the European Economic Area. Subsequent to re-exportation among members of the European Economic Area, controlled substances may continue to be exported between these countries under specific conditions. Controlled substances can be exported between countries in the European Economic Area under specific conditions, ensuring compliance with regulations for each subsequent country involved in the export process. In paragraph (6), re-exportation among members of the European Economic Area requires documentation certifying the re-exportation and information about the consignee, country, and product to be delivered to the Attorney General within 30 days. The Attorney General is limited in regulating re-exportation of controlled substances among European Economic Area countries, including not enforcing time constraints on re-exportation. The Attorney General is limited in regulating re-exportation of controlled substances among European Economic Area countries, including not enforcing time constraints on re-exportation. Re-exportation between countries must occur within a specified period or require information on consignee, country, and product prior to exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}